TERAPET Announces Partnership With Anzai Medical in Japan
Share this article
This collaboration represents an important milestone in TERAPET’s international growth strategy and reinforces the company’s mission to make particle therapy safer, smarter, and more adaptive through imaging-driven verification.
Anzai Medical Co., Ltd., a leading provider of advanced medical technologies in Japan. Under this agreement, Anzai Medical will serve as Geneva-based medtech company TERAPET’s exclusive distributor in Japan, supporting the introduction and adoption of TERAPET’s flagship platform Qualyscan® in clinical particle therapy workflows at leading centers of excellence nationwide.
This collaboration represents an important milestone in TERAPET’s international growth strategy and reinforces the company’s mission to make particle therapy safer, smarter, and more adaptive through imaging-driven verification.
TERAPET’s Qualyscan® enables end-to-end verification of particle beam delivery by combining advanced PET detector technology, radiation-tolerant electronics, and dedicated reconstruction software, providing clinical teams with clear, actionable insights to strengthen QA routines and clinical confidence.
Japan remains one of the most advanced and innovation-driven markets in particle therapy globally, with strong clinical expertise and a growing demand for solutions that can support high-efficiency, data-driven workflows. Through Anzai Medical’s strong presence and established relationships across Japan’s particle therapy community, TERAPET aims to accelerate access to Qualyscan and expand its clinical impact.
Christina Vallgren, CEO of TERAPET SA, said:
“We are excited to partner with Anzai Medical, a highly respected company with a long track record of supporting leading radiation oncology and particle therapy centers in Japan. Their expertise, reach, and commitment to quality align perfectly with TERAPET’s mission. Together, we look forward to bringing Qualyscan® to more clinical teams and supporting the continued advancement of particle therapy in Japan.”
Masaaki Yasue, President of Anzai Medical Co., Ltd., said:
“We are pleased to enter into this partnership with TERAPET and support the introduction of Qualyscan® in Japan. As an established provider of advanced medical technologies for radiation oncology, we believe this collaboration will contribute to further strengthening clinical practice and supporting high-quality treatment delivery at particle therapy centers across the country.”
➡️ Source: TERAPET Press Release | 📸 ©TERAPET